GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Median PS Value

CureVac NV (WBO:CVAC) Median PS Value : €0.00 (As of Jun. 08, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €0.264. CureVac NV's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.

As of today (2024-06-08), CureVac NV's share price is €4.28. CureVac NV's Median PS Value is €0.00. Therefore, CureVac NV's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for CureVac NV's Median PS Value or its related term are showing as below:

WBO:CVAC's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.68
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

CureVac NV Median PS Value Historical Data

The historical data trend for CureVac NV's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Median PS Value Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

CureVac NV Quarterly Data
Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CureVac NV's Median PS Value

For the Biotechnology subindustry, CureVac NV's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Median-PS-Value falls into.



CureVac NV Median PS Value Calculation

CureVac NV's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0.264*0
=0.00

10-Year Median PS Ratio is 0.
CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.264.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV  (WBO:CVAC) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

CureVac NV's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=4.28/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CureVac NV Median PS Value Related Terms

Thank you for viewing the detailed overview of CureVac NV's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (WBO:CVAC) Business Description

Traded in Other Exchanges
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.

CureVac NV (WBO:CVAC) Headlines

From GuruFocus

CureVac Announces Proposed Public Offering of Common Shares

By ACCESSWIRE ACCESSWIRE 02-07-2023